BMS-142 is a PDL1 inhibitor ( IC 50 = 96.7 nM) ( k d = 13.2 nM). BMS-142 can reduce the survival rate of acute T-lymphoblastic leukemia cells and ovarian cancer cells. BMS-142 can be used in research on cancers such as acute T-lymphoblastic leukemia and ovarian cancer .
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PD-1/PD-L1
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.